The article is dedicated to study of efficacy and safety of ibandronic acid administered intravenously to 25 patients suffering from juvenile arthritis and system osteoporosis. It was concluded that administration of 3 mg of ibandronate every 3 months during 76 weeks increase CTX, which indicates improvement of bone metabolism. During the treatment no subsequent vertebrae fractures have been registered. Increase in bone mass during the ibandronate therapy has been sufficient to allow endoprosthetic hip replacement in 7 patients.Key words: child, juvenile arthritis, osteoporosis, treatment, biophosphates, ibandronic acid. (Voprosy sovremennoi pediatrii — Current Pediatrics. — 2011; 10 (6): 83–88)

Search for and practical application of new medications to treat of osteoporosis is one of the critical issues in pediatric rheumatology. The article reviews the efficacy and safety of alendronic acid in 64 subjects with juvenile rheumatoid arthritis and systemic osteoporosis. It is demonstrated that alendronate-based therapy in weekly 1 mg/kg doses over 12 months facilitated reliably increased bonedensity, decreased intensity of pain syndrome, and lowered C-terminal telopeptide serum concentration, which indicates improved bone metabolism processes . Key words: juvenile rheumatoid arthritis, osteoporosis, children, treatment, bisphosphonates, alendronic acid. (Pediatric Pharmacology. – 2010; 7(1):48-54)